19 January 2016 - Genmab A/S announced today that the U.S. FDA has approved a supplemental Biologics License Application for the use of Arzerra (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukaemia. The application was submitted by Novartis under the ofatumumab collaboration between the two companies.

For more details, go to: http://ir.genmab.com/releasedetail.cfm?ReleaseID=950799